CoChat
Sign Up
Cited by 296Cancer-related molecular mechanisms researchLung Cancer Research StudiesMicroRNA in disease regulation

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer

Open access
Liao, Jipei, Yu, Lei, Mei, Yuping, Guarnera, Maria, Shen, Jun, Li, Ruiyun, Liu, Zhenqiu, Jiang, Feng·2010·Molecular Cancer
DOI 10.1186/1476-4598-9-198PMC PMC2919450
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death. Early detection of NSCLC will improve its outcome. The current techniques for NSCLC early detection are either invasive or have low accuracy. Molecular analyses of clinical specimens present promising diagnostic approaches. Non-coding RNAs (ncRNAs) play an important role in tumorigenesis and could be developed as biomarkers for cancer. Here we aimed to develop small nucleolar RNAs (snoRNAs), a common class of ncRNAs, as biomarkers for NSCLC early detection. The study comprised three phases: (1) profiling snoRNA signatures in 22 NSCLC tissues and matched noncancerous lung tissues by GeneChip Array, (2) validating expressions of the signatures by RT-qPCR in the tissues, and (3) evaluating plasma expressions of the snoRNAs in 37 NSCLC patients, 26 patients with chronic obstructive pulmonary disease (COPD), and 22 healthy subjects. Results: In the surgical tissues, six snoRNAs were identified, which were overexpressed in all tumour tissues compared with their normal counterparts. The overexpressions of the genes in tumors were confirmed by RT-qPCR. The snoRNAs were stably present and reliably detectable in plasma. Of the six genes, three (SNORD33, SNORD66 and SNORD76) displayed higher plasma expressions in NSCLC patients compared with the cancer-free individuals (All < 0.01). The use of the three genes produced 81.1% sensitivity and 95.8% specificity in distinguishing NSCLC patients from both normal and COPD subjects. The plasma snoRNA expressions were not associated with stages and histological types of NSCLC (All > 0.05). Conclusions: The identified snoRNAs provide potential markers for NSCLC early detection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1476-4598-9-198

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 SnoRNAs differentially expressed in 22 stage I non-small-cell lung cancer (NSCLC) tissues versus normal lung tissues. Hierarchical clustering of 31 snoRNA genes with a significantly different expression (p < 0.01) in tumour tissues. Rows represent individual genes; columns represent individual tissue samples. The scale stands for the intensity of gene expression (log2 scale ranges between -3.5 and 3.5).
Figure 1 SnoRNAs differentially expressed in 22 stage I non-small-cell lung cancer (NSCLC) tissues versus normal lung tissues. Hierarchical clustering of 31 snoRNA genes with a significantly different expression (p < 0.01) in tumour tissues. Rows represent individual genes; columns represent individual tissue samples. The scale stands for the intensity of gene expression (log2 scale ranges between -3.5 and 3.5).CC BY · PubMed Central
Figure 2 Plasma expression levels of the six snoRNAs in 22 healthy controls, 26 patients with chronic obstructive pulmonary disease (COPD), and 37 patients with non-small-cell lung cancer (NSCLC). Horizontal lines denote mean values. *, statistical significance (< 0.01) of expression levels of snoRNA between NSCLC patients and healthy controls. †, statistical significance (< 0.01) of expression levels of snoRNA between COPD patients and healthy controls. ‡, statistical significance (< 0.01) of expression levels of snoRNA between NSCLC patients and COPD patients.
Figure 2 Plasma expression levels of the six snoRNAs in 22 healthy controls, 26 patients with chronic obstructive pulmonary disease (COPD), and 37 patients with non-small-cell lung cancer (NSCLC). Horizontal lines denote mean values. *, statistical significance (< 0.01) of expression levels of snoRNA between NSCLC patients and healthy controls. †, statistical significance (< 0.01) of expression levels of snoRNA between COPD patients and healthy controls. ‡, statistical significance (< 0.01) of expression levels of snoRNA between NSCLC patients and COPD patients.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 1

  1. Colby TV, Noguchi M, Henschke C: Pathology and Genetics, Tumours of the Lung, Pleura, Thymus and Heart. Adenocarcinoma. Edited by: Travis WD, Brambilla E, Muller-Hermelink HK. 2005, 35-44. Lyon, France: IARC Press,

Cited by

Sorted by citations

Items 101–200 of 296

Related

See all

Metadata

Authors
Liao, J., Yu, L., Mei, Y., Guarnera, M., Shen, J., Li, R., Liu, Z., & Jiang, F.
Affiliations
University of Maryland, Baltimore (US)
Corresponding author
Jiang, Feng
ORCID
Venue
Molecular Cancer
Publisher
Springer Science and Business Media LLC
Published
2010-07-27
Volume
9
Issue
1
Pages
198-198
ISSN
1476-4598 (ISSN-L)
DOI
10.1186/1476-4598-9-198
PMC
PMC2919450
OpenAlex
W2120920586
Cited by
293
References
51
Citations by year
2026: 8 · 2025: 18 · 2024: 25 · 2023: 15 · 2022: 22 · 2021: 28 · 2020: 14 · 2019: 17 · 2018: 23 · 2017: 24 · 2016: 19 · 2015: 23 · 2014: 20 · 2013: 11 · 2012: 17
FWCI
3.72
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Flight Attendant Medical Research Institute
  • National Institutes of Health (5k12rr023250-05)
  • National Cancer Institute (CA137742, R21CA135382, R03CA133956, CA135382, R03CA137742, CA-133956)
  • National Center for Research Resources (K12-RR023250)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
non-small cell lung cancer, small nucleolar RNA, tumor markers, early cancer detection, plasma biomarkers, non-coding RNA, chronic obstructive pulmonary disease, gene expression profiling
MeSH terms
Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, RNA, Small Nuclear, Biomarkers, Tumor, Case-Control Studies, Reverse Transcriptase Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review